CSS
OTLK icon

Cubist Systematic Strategies’s Outlook Therapeutics OTLK Stock Holding History

Cubist Systematic Strategies’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.61K Buy
5,295
+5,269
+20,265% +$9.11K ﹤0.01% 2936
2025
Q2 		$42 Buy
+26
New +$41 ﹤0.01% 2889

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's OTLK Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Outlook Therapeutics (OTLK) stake by 20,265% in Q3 2025, buying an estimated $9.11K and bringing the position to 5,295 shares worth $5.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Cubist Systematic Strategies first reported a position in OTLK in Q2 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • Cubist Systematic Strategies held 5,295 shares of Outlook Therapeutics worth $5.61K as of Q3 2025.
  • Cubist Systematic Strategies bought 5,269 Outlook Therapeutics shares in Q3 2025, an estimated $9.11K.
  • Outlook Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2936 holding.
  • Cubist Systematic Strategies first reported a position in Outlook Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.